(Q35086827)

6 August 2017

1 reference

title

Prostate cancer: advances in immunotherapy (English)

1 reference

6 August 2017

1 reference

1 reference

4

James P Allison

0 references

author name string

Arthur A Hurwitz

1

1 reference

6 August 2017

Paul Yanover

2

1 reference

6 August 2017

Mary Markowitz

3

1 reference

6 August 2017

Eugene D Kwon

5

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

17

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

131-138

1 reference

Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model

6 August 2017

cites work

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2165/00063030-200317020-00005

Clinical use of tumor markers in oncology

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2165/00063030-200317020-00005

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2165/00063030-200317020-00005

Interleukin-2-induced growth inhibition of prostatic adenocarcinoma (Dunning R3327) in rats

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2165/00063030-200317020-00005

Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell lines

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2165/00063030-200317020-00005

CTLA-4--the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2165/00063030-200317020-00005

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2165/00063030-200317020-00005

Target antigens for prostate cancer immunotherapy.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2165/00063030-200317020-00005

Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2165/00063030-200317020-00005

Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2165/00063030-200317020-00005

Identifiers

DOI

10.2165/00063030-200317020-00005

1 reference

Dimensions Publication ID

6 August 2017

1021802817

0 references

1 reference